BASFY vs IFF: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BASFY is the larger of the two ($53.94B market cap): the incumbent the market prices for continued execution (20.59x forward earnings, beta 0.75). IFF is the smaller challenger ($20.65B), priced similarly on forward earnings (21.34x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

BASFY vs IFF: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBASFYIFFWhat it tells you
Market cap$53.94B$20.65BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E20.5921.34Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E23.46235.69Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.750.88Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range76% of range62% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.271.56How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how BASFY and IFF affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BASFY and IFF share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BASFY and IFF exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does BASF SE (BASFY) do?

BASF SE, headquartered in Ludwigshafen, Germany, is the largest chemical producer in the world by sales, with group revenue of about €59.7 billion in 2025. It makes the building blocks of modern industry: basic chemicals and petrochemicals from its integrated Verbund sites, engineering plastics and polyurethanes, battery and catalyst materials, nutrition and personal care ingredients, and crop protection products and seeds through its Agricultural Solutions division. The Verbund model, in which plants at a single site feed each other's by-products and energy, is the company's core competitive idea, and Ludwigshafen is the largest integrated chemical complex on earth. In 2025 BASF started up the main plants at a new Verbund site in Zhanjiang, China, a roughly €8.7 billion bet that the world's biggest chemical market will keep growing. The US-traded BASFY is a sponsored Level I ADR on OTCQX, with BNY Mellon as depositary and four ADRs representing one ordinary share listed on Xetra under the ticker BAS.

Full BASFY guide

What does International Flavors & Fragrances Inc. (IFF) do?

International Flavors & Fragrances makes the taste, scent and functional ingredients that go into other companies' products: flavor systems for beverages, snacks and dairy, fine and consumer fragrances, enzymes, cultures, probiotics and soy proteins. The company traces to 1833 and reached its current scale through the 2018 Frutarom acquisition and the February 2021 Reverse Morris Trust merger with DuPont's Nutrition & Biosciences division, a roughly $26 billion combination that made IFF one of the four global ingredient houses alongside Givaudan, dsm-firmenich and Symrise. As of the second quarter of 2026 it reports three continuing segments, Taste (~$688 million of quarterly sales), Health & Biosciences (~$601 million) and Scent (~$665 million), after moving the Food Ingredients and Soy Crush businesses into discontinued operations.

Full IFF guide

BASFY vs IFF: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • BASFY drivers: Earnings recovery and raised 2026 guidance; Portfolio reshaping: coatings out, agriculture toward an IPO.
  • IFF drivers: The Food Ingredients sale and the capital return attached to it; Deleveraging from the DuPont merger is essentially complete.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: BASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year. For IFF, the CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked.

BASFY or IFF: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BASFY if you believe its drivers more; IFF if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BASFY and IFF guides.

BASFY vs IFF: the full fundamentals

BASFY. BASF shares traded around €53 in early autumn 2026, which puts the ADR in the mid-teens in dollars given the four-for-one ratio. On the guided 2026 EBITDA before special items, the stock trades at a mid-single-digit EV/EBITDA multiple once net debt and pensions are added back, which is typical for European commodity-heavy chemical producers and cheaper than US specialty peers. Reported net income in 2026 is inflated by the roughly €3.9 billion coatings disposal gain, so trailing P/E figures quoted on data sites can look misleadingly low and are best read alongside the underlying EBITDA trend.

IFF. The two revenue figures are not a contradiction: trailing revenue of ~$10.8 billion covers the whole company, while 2026 guidance of ~$7.4 billion to ~$7.6 billion covers only the three segments IFF is keeping, since Food Ingredients and the Soy Crush businesses moved to discontinued operations in the second quarter. Trailing GAAP EPS of ~$1.01 puts the shares near 90 times earnings, a number distorted by amortization and disposal charges, which is why the forward multiple of roughly 23 times on ~$3.96 of expected 2027 EPS is the one most analysts quote. Yahoo Finance puts enterprise value near 15 times trailing EBITDA, while Food Ingredients is being sold at roughly 8 times its own EBITDA; 17 analysts carry a mean target near ~$97.

Headline figures (approximate, October 2026): BASFY shows revenue (fy 2025) ~€59.7B (~$69B), ebitda before special items (fy 2025) ~€6.6B, 2026 ebitda before special items guidance €6.9B to €7.7B (raised in July), q2 2026 sales / ebitda bsi ~€17.2B / ~€2.4B; IFF shows revenue (ttm, all businesses) ~$10.8B; Q2 2026 ~$2.78B including discontinued operations, fy 2026 sales guidance (continuing operations) ~$7.4B to ~$7.6B; consensus ~$7.59B, q2 2026 adjusted operating ebitda margin ~20.9%, eps ~$1.01 trailing GAAP; 2026 consensus ~$3.29, 2027 ~$3.96.

The bottom line: BASFY vs IFF

BASFY and IFF are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BASFY and IFF exposure against your real portfolio. It is not an investment adviser.

Wondering how BASFY or IFF fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about BASF SE

Ask Walnut's AI anything about BASFY and see how it fits what you own.

FAQ

What is the difference between BASFY and IFF?

+

BASF SE, headquartered in Ludwigshafen, Germany, is the largest chemical producer in the world by sales, with group revenue of about €59.7 billion in 2025. International Flavors & Fragrances makes the taste, scent and functional ingredients that go into other companies' products: flavor systems for beverages, snacks and dairy, fine and consumer fragrances, enzymes, cultures, probiotics and soy proteins. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BASFY or IFF the better stock?

+

Neither is universally better. BASFY is the larger incumbent; IFF is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BASFY or IFF?

+

On forward P/E (as of November 2026), BASFY trades at 20.59x and IFF at 21.34x, so BASFY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BASFY and IFF?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BASFY vs IFF?

+

BASFY: BASF is a cyclical company, and chemical prices, volumes and margins can turn quickly with industrial production, construction and auto demand, so a strong quarter can reverse within a year. European natural gas and power costs remain structurally higher than in the US and the Middle East, which puts Ludwigshafen at a competitive disadvantage and makes further restructuring charges likely. Chinese overcapacity in many basic chemicals pressures global pricing, which affects both European margins and the returns on the Zhanjiang investment. A large acquisition such as Evonik would bring integration risk, possible antitrust remedies and higher debt, and could crowd out the buyback plans. BASF also carries litigation exposure (including PFAS-related claims in the US, where BASF Corporation settled with public water systems in 2024 but continues to defend other cases), and for US holders the euro to dollar exchange rate and German dividend withholding tax affect what the ADR actually returns. IFF: The CVC transaction is not expected to close until the end of the second quarter of 2027 and remains subject to regulatory approvals, so both the $2.0 billion post-close buyback and the promised debt paydown are contingent rather than banked. Stranded costs are the near-term execution problem: roughly $3.2 billion of sales and ~$520 million of EBITDA leave the company, and the overhead that supported them has to be removed for the stated margin uplift to be real. GAAP earnings remain thin relative to the market value, with trailing continuing-operations net income of ~$277 million against a ~$23 billion capitalization (Yahoo Finance shows a ~$791 million trailing loss once discontinued operations are included), because ~$948 million of annual depreciation and amortization and a string of disposal charges sit between EBITDA and reported profit. After a ~45% one year rally the shares also carry less valuation cushion if the November 3 report disappoints, and Yahoo Finance records second quarter EPS of ~$0.82 against a ~$1.12 estimate, though the reclassification of Food Ingredients muddies that comparison. Goodwill of ~$8.1 billion and intangibles of ~$3.7 billion still make up a large share of a ~$14.0 billion equity base that already absorbed multi-billion-dollar impairments in 2022 and 2023, so further writedowns are possible if end markets soften. Antitrust exposure is also open: European Commission, UK CMA and Swiss inspections of fragrance pricing continue, and while IFF settled the U.S. civil class actions for roughly $43 million in provisions, an Israeli class action over a Frutarom-era bonus was certified in September 2025 with a rehearing motion still pending.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BASFY or IFF; figures are approximate and dated (as of November 2026). Verify current data before investing.